Analytical Data
-
Gene name
Slc7a10
- Application
-
Alternative Names
D-serine transporter Solute carrier family 7 member 10
-
Species
Mouse
-
Source
Yeast
-
Tag
N- His-sumostar
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P63115
-
Expression Region
475-530aa
-
Molecular Weight
22.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Slc7a10, a member of the solute carrier family, encodes a sodium-dependent neutral amino acid transporter primarily expressed in the brain. Research has gained interest in Slc7a10 due to its role in neurotransmitter transport and its potential implications in neurological disorders. This protein is known to facilitate the uptake of amino acids such as alanine and serine, which are essential for protein synthesis and neurotransmitter regulation. Dysregulation of Slc7a10 function has been linked to various neuropsychiatric conditions, making it a significant target for investigating the molecular mechanisms underlying these disorders. The recombination and purification of Slc7a10 provide valuable insights into its structural and functional properties, allowing for the exploration of its transport mechanism and interaction with substrates. By studying Slc7a10 in a controlled environment, researchers aim to unravel its role in neuronal health and its potential as a therapeutic target. Additionally, recombinant protein studies facilitate high-throughput screening for compounds that modulate Slc7a10 activity, paving the way for novel treatments for related disorders. Overall, the research on Slc7a10 recombinant proteins is crucial for understanding its biological significance and advancing therapeutic approaches for treating neurological diseases.
